{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:20:52Z","timestamp":1793136052181,"version":"4.5.0"},"reference-count":35,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2012,6,4]],"date-time":"2012-06-04T00:00:00Z","timestamp":1338768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Exper Ophthalmology"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>A<jats:sc>bstract<\/jats:sc><\/jats:title><jats:p><jats:bold>Background:\u2002<\/jats:bold> To determine whether postoperative subconjunctival bevacizumab significantly alters bleb vascularity.<\/jats:p><jats:p><jats:bold>Design:\u2002<\/jats:bold> A randomized, prospective interventional study.<\/jats:p><jats:p><jats:bold>Participants:\u2002<\/jats:bold> Forty\u2010three eyes from 39 patients were recruited, with 21 eyes randomized to subconjunctival injections of 5\u2010fluorouracil, and 22 eyes to combined 5\u2010fluorouracil\/bevacizumab.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> All patients who underwent uncomplicated primary antimetabolite augmented trabeculectomy who subsequently required postoperative subconjunctival 5\u2010fluorouracil injection within 4 weeks of surgery were eligible. Patients were randomized to receive subconjunctival 5\u2010fluorouracil only (7.5\u2003mg\/0.15\u2003mL) or 5\u2010fluorouracil plus bevacizumab (1.25\u2003mg\/0.05\u2003mL).<\/jats:p><jats:p><jats:bold>Main Outcome Measures:\u2002<\/jats:bold> Primary outcome was bleb vascularity with secondary endpoints including visual acuity, intraocular pressure, bleb morphology, complications and total numbers of 5\u2010fluorouracil injections were recorded at baseline, week 12 and 18 months.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> At week 12, there was no significant difference between groups for visual acuity, intraocular pressure, bleb vascularity and morphology, or total number of 5\u2010fluorouracil injections. By 18 months, 47.4% of the 5\u2010fluorouracil\/bevacizumab group exhibited central bleb avascularity compared with 21.1% of the 5\u2010fluorouracil group (Fisher's exact test, <jats:italic>P<\/jats:italic>\u2003=\u20030.17). Two bleb complications (one blebitis; one suture abscess) recorded in the 5\u2010fluorouracil\/bevacizumab group.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> After a single combined injection, a trend for increased central bleb avascularity was observed, although this effect was not sufficient to reach statistical significance. This, in addition to the occurrence of two bleb\u2010related complications in the bevacizumab group, suggests the need for a larger clinical trial to further evaluate the safety and efficacy of bevacizumab as a modulating agent in glaucoma filtration surgery.<\/jats:p>","DOI":"10.1111\/j.1442-9071.2012.02798.x","type":"journal-article","created":{"date-parts":[[2012,3,19]],"date-time":"2012-03-19T14:56:21Z","timestamp":1332168981000},"page":"773-779","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Bleb vascularity following post\u2010trabeculectomy subconjunctival bevacizumab: a pilot study"],"prefix":"10.1111","volume":"40","author":[{"given":"Brian E","family":"Chua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Q","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Queena","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan B","family":"Ruddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuwan","family":"Niyadurupola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viney","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina T","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Coote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G","family":"Crowston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,6,4]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2008.01896.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.140129"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.08.009"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(08)01117-5"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.2174\/157016109788340640"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0302"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdrc.10024"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(09)17517-9"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2008.04.023"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/SAP.0b013e3181828141"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20938"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2662"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5669"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.06.009"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2441"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-3949"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e31821826b2"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.03.025"},{"key":"e_1_2_6_20_2","first-page":"797","article-title":"Low\u2010dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma","volume":"5","author":"Sedghipour MR","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2011.02608.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.08.005"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200412000-00005"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e3283360aad"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.03.013"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3928\/1542-8877-20060301-12","article-title":"Needle bleb revision of encapsulated filtering bleb with bevacizumab","volume":"37","author":"Kahook MY","year":"2006","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"e_1_2_6_27_2","first-page":"837","article-title":"Subconjunctival injection(s) of bevacizumab for failing filtering blebs","volume":"48","author":"Kapetansky FM","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_6_28_2","first-page":"4165","article-title":"Effect of needle bleb revision with ranibizumab as a primary intervention in a failing bleb following trabeculectomy","volume":"49","author":"Purcell JM","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e31815f5345"},{"key":"e_1_2_6_30_2","first-page":"4815","article-title":"Bevacizumab binding to human sclera post topical application","volume":"48","author":"Yu JY","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-3148"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00133.2005"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2004.06.028"},{"key":"e_1_2_6_34_2","first-page":"2175","article-title":"Bevacizumab therapy normalizes the pathological intraocular environment beyond neutralizing VEGF","volume":"16","author":"Sharma RK","year":"2010","journal-title":"Mol Vis"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2005.05.006"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/msb4100163"}],"container-title":["Clinical &amp; Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1442-9071.2012.02798.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1442-9071.2012.02798.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T22:00:02Z","timestamp":1697407202000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1442-9071.2012.02798.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,4]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1111\/j.1442-9071.2012.02798.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1442-9071.2012.02798.x","archive":["Portico"],"relation":{},"ISSN":["1442-6404","1442-9071"],"issn-type":[{"value":"1442-6404","type":"print"},{"value":"1442-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,4]]},"assertion":[{"value":"2012-06-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}